checkAd

     125  0 Kommentare Claritas Announces Completion of IND-Enabling In Vitro Genotoxicity Studies with R-107 - Seite 4

    Contact Information
    Robert Farrell
    President, CEO
    (888) 861-2008
    info@claritaspharma.com


     

    globenewswire
    0 Follower
    Autor folgen
    RSS-Feed abonnieren

    Weitere Artikel des Autors

    Seite 4 von 4

    Verfasst von globenewswire
    1 im Artikel enthaltener WertIm Artikel enthaltene Werte
    Claritas Announces Completion of IND-Enabling In Vitro Genotoxicity Studies with R-107 - Seite 4 SAN FRANCISCO and TORONTO, April 01, 2021 (GLOBE NEWSWIRE) - Claritas Pharmaceuticals, Inc. (formerly Kalytera Therapeutics, Inc.) (TSX VENTURE: KLY and OTC: KALTF) (the "Company" or "Claritas") today announced that it has completed GLP …